NO20064829L - Gossypol-co-krystaller og anvendelse derav - Google Patents

Gossypol-co-krystaller og anvendelse derav

Info

Publication number
NO20064829L
NO20064829L NO20064829A NO20064829A NO20064829L NO 20064829 L NO20064829 L NO 20064829L NO 20064829 A NO20064829 A NO 20064829A NO 20064829 A NO20064829 A NO 20064829A NO 20064829 L NO20064829 L NO 20064829L
Authority
NO
Norway
Prior art keywords
gossypol
crystals
relates
carboxylic acid
sulfonic acid
Prior art date
Application number
NO20064829A
Other languages
English (en)
Inventor
Shaomeng Wang
Dajon Yang
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of NO20064829L publication Critical patent/NO20064829L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Denne oppfinnelsen vedrører preparater som omfatter ko-krystaller av (-)-gossypol med en C1-8-karboksylsyre eller C1-8-sulfonsyre som er nyttige som inhibitorer av Bcl-2-familieproteiner. Oppfinnelsen vedrører også anvendelsen av ko-krystaller av (-)-gossypol med en C1-8-skarboksylsyre eller C1-8-sulfonsyre for å indusere apoptose i celler og for å sensitivisere celler for induksjonen av apoptotisk celledød.
NO20064829A 2004-03-25 2006-10-24 Gossypol-co-krystaller og anvendelse derav NO20064829L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55624904P 2004-03-25 2004-03-25
PCT/US2005/009673 WO2005094804A1 (en) 2004-03-25 2005-03-24 Gossypol co-crystals and the use thereof

Publications (1)

Publication Number Publication Date
NO20064829L true NO20064829L (no) 2006-12-20

Family

ID=35063489

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064829A NO20064829L (no) 2004-03-25 2006-10-24 Gossypol-co-krystaller og anvendelse derav

Country Status (15)

Country Link
US (3) US7342046B2 (no)
EP (1) EP1732529A4 (no)
JP (1) JP2007530568A (no)
KR (2) KR20080097496A (no)
CN (1) CN1960719B (no)
AU (2) AU2005228998B2 (no)
BR (1) BRPI0509182A (no)
CA (1) CA2561303C (no)
EA (1) EA011218B1 (no)
IL (1) IL178286A0 (no)
MX (1) MXPA06010938A (no)
NO (1) NO20064829L (no)
SG (1) SG151299A1 (no)
WO (1) WO2005094804A1 (no)
ZA (1) ZA200607956B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
JP2006518343A (ja) * 2003-01-17 2006-08-10 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド エネルギー減損因子を用いた良性前立腺増殖症の処置
MXPA06010938A (es) * 2004-03-25 2007-01-25 Univ Michigan Co-cristales de gossipol y el uso de los mismos.
CA2689033A1 (en) * 2007-05-31 2008-12-11 Ascenta Therapeutics, Inc. Pulsatile dosing of gossypol for treatment of disease
JP2010539245A (ja) 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
US7696372B2 (en) * 2007-10-01 2010-04-13 Ascenta Therapeutics, Inc. Process for preparing R-gossypol L-phenylalaninol dienamine
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
RU2497835C2 (ru) 2007-12-28 2013-11-10 Бриджстоун Корпорейшн Гидроксиарилфункционализованные полимеры
US20110144125A1 (en) * 2008-08-14 2011-06-16 The Uab Research Foundation Anti-Arrhythmia Agents, Methods of Their Use, Methods of Their Identification and Kits Therefore
KR101738709B1 (ko) 2009-06-30 2017-05-22 가부시키가이샤 브리지스톤 히드록실기 함유 디페닐에틸렌으로 관능화된 중합체
US8440755B2 (en) * 2009-07-01 2013-05-14 Bridgestone Corporation Method of making hydroxyaryl-functionalized interpolymer
CN101810577B (zh) * 2010-05-06 2011-09-07 山东大学 治疗肿瘤的棉酚静脉注射脂肪乳剂
CN103038204B (zh) 2010-05-31 2015-03-04 株式会社普利司通 含羟基的甲基苯乙烯和引入其的聚合物
KR101408370B1 (ko) * 2012-06-26 2014-06-18 주식회사지씨비 아리피프라졸-유기산 공결정을 함유하는 제제 및 이의 제조 방법
KR101579371B1 (ko) 2014-02-27 2015-12-22 국립암센터 고시폴 및 펜포르민을 유효성분으로 함유하는 암 치료용 약제학적 조성물
EP3417853B1 (en) 2016-02-18 2024-06-05 Industry-Academic Cooperation Foundation Yonsei University Pharmaceutical composition for treatment of stomach cancer containing gossypol, phenformin and irinotecan
JP7564619B2 (ja) * 2017-02-22 2024-10-09 ナショナル キャンサー センター ゴシポールおよびフェンホルミンを有効成分として含む膵臓癌予防および治療用薬学的組成物
WO2018192573A1 (zh) * 2017-04-22 2018-10-25 秦才东 一种抑制细胞糖酵解过程的方法及应用
KR102259892B1 (ko) * 2019-08-05 2021-06-04 주식회사 하임바이오 식물유래 폴리페놀염의 대량 제조 방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3364242A (en) * 1963-07-05 1968-01-16 Swift & Co Separation of gossypol from cottonseed oil
US3347885A (en) * 1966-01-03 1967-10-17 Anderson Clayton & Co Inc Cottonseed oil direct extraction method
US3647791A (en) * 1967-09-19 1972-03-07 Ciba Geigy Corp 2 3 4 4a 5 6-hexahydro - 1h - pyrazino (1 2-a) quinolines and pharmaceutical compositions containing same
DE1917341C3 (de) 1969-04-03 1973-10-18 Wsesojusnyj Nautschno-Issledowatelskij Institut Schirow, Leningrad (Sowjetunion) Verfahren zur Gewinnung von Baum wollsaatol
SU322042A1 (ru) 1969-07-15 1976-02-15 Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узбекской Сср Способ очистки госсипола
NL7303876A (no) 1972-03-30 1973-10-02
US4297341A (en) * 1980-05-09 1981-10-27 University Of Illinois Foundation Spermicidal composition
SU1351915A1 (ru) 1982-06-16 1987-11-15 Институт Биоорганической Химии Ан Узсср Способ получени госсипола из антранилата госсипола
US4747979A (en) * 1984-07-02 1988-05-31 The Dow Chemical Company Removal of toxins from cottonseed
US4806568A (en) * 1985-09-12 1989-02-21 Research Corporation Gossypol derivatives
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
JPH01132542A (ja) 1987-11-19 1989-05-25 Toomen:Kk ゴッシポールラセミ体の光学分割法
CN1017705B (zh) 1987-12-26 1992-08-05 中国医学科学院药物研究所 制备光学活性棉酚的方法
CH676360A5 (en) 1988-12-28 1991-01-15 Inst Bioorg Khim Nauk Uzbexkoi Purificn. of antiviral gossypol cpd. - by recrystallisation from ether with hexane
US5059717A (en) * 1989-01-05 1991-10-22 Ibragimov Bakhtiyar T Method for purification of 2,2'-di(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-naphthaldehyde)
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
CN1044455A (zh) 1989-01-25 1990-08-08 乌兹别克苏维埃共和国科学院生物有机化学研究所 2，2，-二(1，6，7-三羟基-3-甲基-5-异丙基-8-萘甲醛)的纯化方法
US5026726A (en) * 1989-12-11 1991-06-25 The University Of New Mexico Gossylic iminolactones and gossylic lactones and their anti-viral activities
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5277909A (en) * 1990-08-24 1994-01-11 The United States Of America, As Represented By The Secretary Of Agriculture Method for removal of gossypol from cottonseed meal by the use of urea in a borate containing buffer
US5077441A (en) * 1990-10-05 1991-12-31 The United States Of America As Represented By The Secretary Of Agriculture Selective gossypol abatement process from oil extraction of cottonseed
US5112637A (en) * 1990-11-05 1992-05-12 The United States Of America As Represented By The Secretary Of Agriculture Extraction of gossypol from cottonseed
RU2067111C1 (ru) 1992-06-16 1996-09-27 Узбекский научно-исследовательский институт химической технологии катализа им.А.Султанова Способ получения госсипола из сырого черного хлопкового масла
DE69332353T2 (de) 1992-07-24 2003-07-10 The Johns Hopkins University, Baltimore Verwendung von inhibitoren der synthese von fettsäuren zur behandlung von krebs
CZ224195A3 (en) 1993-03-01 1996-03-13 Merck Sharp & Dohme The use of pyrrolopyridine derivatives for preparing pharmaceutical preparations
CN1094392A (zh) 1993-04-20 1994-11-02 徐世江 碱液提取棉酚法
WO1996004250A1 (en) 1994-08-05 1996-02-15 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
US6094217A (en) * 1994-10-27 2000-07-25 Fuji Photo Film Co., Ltd. Automatic regenerating method for film image
US5780675A (en) * 1995-04-28 1998-07-14 The University Of New Mexico Deoxygossylic compounds
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
EP0827165B1 (en) * 1996-08-31 2001-06-13 Toyo Denso Kabushiki Kaisha Engine igniting coil device
KR20010031501A (ko) * 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6113397A (en) * 1999-02-10 2000-09-05 General Instrument Corporation Coaxial connectors mounted back-to-back on backplane
WO2002041828A2 (en) 2000-11-17 2002-05-30 Dajun Yang Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon
US6608107B2 (en) * 2000-12-15 2003-08-19 Wackvom Limited Methods and compositions to treat conditions associated with neovascularization
ATE474568T1 (de) * 2001-05-30 2010-08-15 Univ Michigan Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US20030082101A1 (en) * 2001-06-11 2003-05-01 Cavalier Discovery Accelerators for increasing the rate of formation of free radicals and reactive oxygen species
US20030119894A1 (en) * 2001-07-20 2003-06-26 Gemin X Biotechnologies Inc. Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
CN1229321C (zh) 2001-09-06 2005-11-30 新疆科赛生物工程有限公司 用二苯胺棉酚生产棉酚的方法
DK1653943T4 (da) * 2003-06-25 2008-12-01 Burnham Inst Catecholderivater til behandling af cancer
MXPA06010938A (es) * 2004-03-25 2007-01-25 Univ Michigan Co-cristales de gossipol y el uso de los mismos.

Also Published As

Publication number Publication date
CN1960719B (zh) 2011-12-07
KR20080097496A (ko) 2008-11-05
EP1732529A4 (en) 2009-02-25
CA2561303A1 (en) 2005-10-13
US20090082445A1 (en) 2009-03-26
EP1732529A1 (en) 2006-12-20
EA011218B1 (ru) 2009-02-27
AU2005228998B2 (en) 2008-11-06
KR20070026473A (ko) 2007-03-08
AU2009200387A1 (en) 2009-02-19
US7342046B2 (en) 2008-03-11
IL178286A0 (en) 2007-03-08
SG151299A1 (en) 2009-04-30
US20070293585A1 (en) 2007-12-20
ZA200607956B (en) 2008-02-27
EA200601562A1 (ru) 2007-02-27
WO2005094804A1 (en) 2005-10-13
KR100906843B1 (ko) 2009-07-08
AU2005228998A1 (en) 2005-10-13
MXPA06010938A (es) 2007-01-25
JP2007530568A (ja) 2007-11-01
US20050234135A1 (en) 2005-10-20
CN1960719A (zh) 2007-05-09
US7432300B2 (en) 2008-10-07
CA2561303C (en) 2011-01-18
BRPI0509182A (pt) 2007-09-18

Similar Documents

Publication Publication Date Title
NO20064829L (no) Gossypol-co-krystaller og anvendelse derav
Yoon et al. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy
Nunes et al. Intestinal anti-inflammatory activity of red wine extract: Unveiling the mechanisms in colonic epithelial cells
NO20085074L (no) Toverdige SMAC-mimetika og anvendelsene derav
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
EA201000797A1 (ru) Аминотриазолы в качестве ингибиторов pi3k
HN2012002664A (es) Compuestos, composiciones de tioacetato y metodos de uso
DK2073647T4 (da) Ketogen diæt
WO2005069894A3 (en) Conformationally constrained smac mimetics and the uses thereof
EA200801716A1 (ru) Тиазольные соединения и их применение
MX2009011069A (es) Mimeticos de smac diazo biciclicos y usos de los mismos.
WO2005069888A3 (en) Smac peptidomimetics and the uses thereof
NO20064584L (no) Tetrahydropyridoindolderivater
BR112014005352A2 (pt) organismos eucarióticos e métodos para aumentar a disponibilidade de acetil-coa citosólico e para produzir 1,3-butanodiol
NO20075731L (no) Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon
Nunes et al. Red wine polyphenol extract efficiently protects intestinal epithelial cells from inflammation via opposite modulation of JAK/STAT and Nrf2 pathways
EA201500650A1 (ru) Фенилацетат l-орнитина и способы его получения
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
Kader et al. Ribose-cysteine increases glutathione-based antioxidant status and reduces LDL in human lipoprotein (a) mice
DK1871374T3 (da) 2,3-substituerede pyrazinsulfonamider som CRTH2-inhibitorer
BRPI1014492A8 (pt) Formação lípida estabilizada de promotor de apoptose
WO2006063175A3 (en) Taurine-based compositions, therapeutic methods, and assays
BR112012012476A2 (pt) "composições nutritivas incluindo um componente de alta proteína e nucleotídeos exôgenos"
AR082943A1 (es) Formula nutricional predigerida

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application